Bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together
The Pharma Data
APRIL 14, 2021
It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.
Let's personalize your content